elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37690095-60FB9E88-40E8-4621-A186-740AFABC77C5
Q37690095-60FB9E88-40E8-4621-A186-740AFABC77C5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37690095-60FB9E88-40E8-4621-A186-740AFABC77C5
The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing.
P2860
Q37690095-60FB9E88-40E8-4621-A186-740AFABC77C5
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37690095-60FB9E88-40E8-4621-A186-740AFABC77C5
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e624e7b84b1858958dbc08a2ee4696b5b0abe4d6
P2860
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.